ROCO
3205
Market cap54mUSD
Jul 10, Last price
48.80TWD
1D
1.56%
1Q
121.32%
Jan 2017
-61.12%
IPO
90.40%
Name
Sagittarius Life Science Corp
Chart & Performance
P/E
—
P/S
3.40
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-18.76%
Revenues
468m
+6.20%
Net income
-49m
L-11.82%
CFO
-44m
L-35.88%
Profile
Sagittarius Life Science Corp researches, develops, and sells Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 467,750 6.20% | 440,460 -16.75% | 529,065 -9.96% | ||
Cost of revenue | 529,311 | 504,836 | 611,294 | ||
Unusual Expense (Income) | |||||
NOPBT | (61,561) | (64,376) | (82,229) | ||
NOPBT Margin | |||||
Operating Taxes | (12) | ||||
Tax Rate | |||||
NOPAT | (61,561) | (64,376) | (82,217) | ||
Net income | (48,531) -11.82% | (55,039) -25.82% | (74,200) -14.14% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | 6,590 | 7,069 | 8,005 | ||
Long-term debt | 14,944 | 19,577 | 14,727 | ||
Deferred revenue | |||||
Other long-term liabilities | 3,887 | 4,442 | 3,941 | ||
Net debt | (215,076) | (399,304) | (245,887) | ||
| Cash flow | |||||
Cash from operating activities | (44,480) | (69,369) | (52,891) | ||
CAPEX | (3,293) | (2,013) | (1,093) | ||
Cash from investing activities | 2,734 | 22,445 | (1,137) | ||
Cash from financing activities | (9,888) | (7,895) | (13,156) | ||
FCF | (63,754) | (63,189) | (66,508) | ||
| Balance | |||||
Cash | 160,902 | 215,384 | 269,720 | ||
Long term investments | 75,708 | 210,566 | (1,101) | ||
Excess cash | 213,222 | 403,927 | 242,166 | ||
Stockholders' equity | 288,335 | 382,153 | 259,482 | ||
Invested Capital | 221,190 | 162,511 | 228,556 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 32,618 | 32,546 | 32,546 | ||
Price | 31.95 -38.79% | 52.20 28.26% | 40.70 48.00% | ||
Market cap | 1,042,138 -38.66% | 1,698,901 28.26% | 1,324,622 48.00% | ||
EV | 838,472 | 1,311,843 | 1,092,356 | ||
EBITDA | (46,805) | (49,345) | (61,314) | ||
EV/EBITDA | |||||
Interest | 207 | 82 | 234 | ||
Interest/NOPBT | |||||